Details of the Drug

General Information of Drug (ID: DM6EUL5)

• Drug Name: Betaxolol
• Synonyms: Betaxololum; Betazolol; KERLEDEX; Kerlone; Betaxolol HCL; SL 75212; Betaxolol (INN); Betaxolol (TN); Betaxolol [INN:BAN]; Betaxololum [INN-Latin]; Betoptic (TN); Betoptic S (TN); Kerlone (TN); Lokren (TN); SL-75212; ALO-1401-02; (+/-)-1-[p-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol; 1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol; 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol; 1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol; 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol; 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]
Malignant essential hypertension	BA00	Approved	[2]
Ocular hypertension	9C61.01	Approved	[2]

• Therapeutic Class: Antihypertensive Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  C07AB05: Betaxolol
  C07AB: Beta blocking agents, selective
  C07A: BETA BLOCKING AGENTS
  C07: BETA BLOCKING AGENTS
  C: CARDIOVASCULAR SYSTEM
  S01ED02: Betaxolol
  S01ED: Beta blocking agents
  S01E: ANTIGLAUCOMA PREPARATIONS AND MIOTICS
  S01: OPHTHALMOLOGICALS
  S: SENSORY ORGANS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 307.4
  Logarithm of the Partition Coefficient (xlogp); 2.8
  Rotatable Bond Count (rotbonds); 11
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: 85% of drug becomes completely available to its intended biological destination(s) [4]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 3.4 mL/min/kg [5]
  Elimination: 15% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 14 - 22 hours [5]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.16955 micromolar/kg/day [6]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.4% [5]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4.8 L/kg [5]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.451 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Adverse drug reaction	Not Available	CYP2D6	OTZJC802	[7]

• Chemical Identifiers:
  Formula: C18H29NO3
  IUPAC Name: 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
  Canonical SMILES: CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O
  InChI: InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
  InChIKey: NWIUTZDMDHAVTP-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2369
  ChEBI ID: CHEBI:3082
  CAS Number: 63659-18-7
  UNII: O0ZR1R6RZ2
  DrugBank ID: DB00195
  TTD ID: D03ROX
  INTEDE ID: DR0206
  ACDINA ID: D00065
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[7]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Betaxolol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Nisoldipine	DM7ISKJ	Moderate	Increased risk of cardiac depression by the combination of Betaxolol and Nisoldipine.	Hypertension [BA00-BA04]	[11]
Levamlodipine	DM92S6N	Moderate	Increased risk of cardiac depression by the combination of Betaxolol and Levamlodipine.	Hypertension [BA00-BA04]	[12]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Betaxolol and Doxazosin.	Hypertension [BA00-BA04]	[13]
Isradipine	DMA5XGH	Moderate	Increased risk of cardiac depression by the combination of Betaxolol and Isradipine.	Hypertension [BA00-BA04]	[12]
Verapamil	DMA7PEW	Major	Increased risk of cardiac depression by the combination of Betaxolol and Verapamil.	Hypertension [BA00-BA04]	[12]
Diltiazem	DMAI7ZV	Major	Increased risk of cardiac depression by the combination of Betaxolol and Diltiazem.	Hypertension [BA00-BA04]	[12]
Amlodipine	DMBDAZV	Moderate	Increased risk of cardiac depression by the combination of Betaxolol and Amlodipine.	Hypertension [BA00-BA04]	[12]
Indapamide	DMGN1PW	Moderate	Increased risk of ventricular arrhythmias by the combination of Betaxolol and Indapamide.	Hypertension [BA00-BA04]	[14]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of hypertriglyceridemia by the combination of Betaxolol and Trichlormethiazide.	Hypertension [BA00-BA04]	[14]
Felodipine	DMOSW35	Moderate	Increased risk of cardiac depression by the combination of Betaxolol and Felodipine.	Hypertension [BA00-BA04]	[12]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Betaxolol and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[14]
Clevidipine butyrate	DMW4M97	Moderate	Increased risk of cardiac depression by the combination of Betaxolol and Clevidipine butyrate.	Hypertension [BA00-BA04]	[12]

Coadministration of a Drug Treating the Disease Different from Betaxolol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sucralfate	DMP9HBO	Minor	Decreased absorption of Betaxolol due to formation of complexes caused by Sucralfate.	Acne vulgaris [ED80]	[15]
Scopolamine	DMOM8AL	Moderate	Altered absorption of Betaxolol due to GI dynamics variation caused by Scopolamine.	Addictive disorder [6C50-6C5Z]	[16]
Bepridil	DM0RKS4	Moderate	Increased risk of cardiac depression by the combination of Betaxolol and Bepridil.	Angina pectoris [BA40]	[12]
Dronedarone	DMA8FS5	Moderate	Increased risk of atrioventricular block by the combination of Betaxolol and Dronedarone.	Angina pectoris [BA40]	[17]
Nifedipine	DMSVOZT	Moderate	Increased risk of cardiac depression by the combination of Betaxolol and Nifedipine.	Angina pectoris [BA40]	[12]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Betaxolol and Promazine.	Appearance/behaviour symptom [MB23]	[18]
Zileuton	DMVRIC2	Moderate	Decreased metabolism of Betaxolol caused by Zileuton.	Asthma [CA23]	[19]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Betaxolol and Cariprazine.	Bipolar disorder [6A60]	[18]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Betaxolol and Atracurium.	Corneal disease [9A76-9A78]	[20]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Betaxolol and Mivacurium.	Corneal disease [9A76-9A78]	[20]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Betaxolol and Pancuronium.	Corneal disease [9A76-9A78]	[20]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Betaxolol and Tubocurarine.	Corneal disease [9A76-9A78]	[20]
Nimodipine	DMQ0RKZ	Moderate	Increased risk of cardiac depression by the combination of Betaxolol and Nimodipine.	Coronary vasospastic disease [BA85]	[12]
Pasireotide	DMHM7JS	Moderate	Increased risk of bradycardia by the combination of Betaxolol and Pasireotide.	Cushing syndrome [5A70]	[21]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Betaxolol and OPC-34712.	Depression [6A70-6A7Z]	[18]
Hyoscyamine	DM804UR	Moderate	Antagonize the effect of Betaxolol when combined with Hyoscyamine.	Digestive system disease [DE2Z]	[16]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Betaxolol when combined with Mepenzolate.	Digestive system disease [DE2Z]	[16]
Oxybutynine	DMJPBAX	Moderate	Altered absorption of Betaxolol due to GI dynamics variation caused by Oxybutynine.	Discovery agent [N.A.]	[16]
Trihexyphenidyl	DMB19L8	Moderate	Antagonize the effect of Betaxolol when combined with Trihexyphenidyl.	Dystonic disorder [8A02]	[16]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of hypertriglyceridemia by the combination of Betaxolol and Bendroflumethiazide.	Essential hypertension [BA00]	[14]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Betaxolol and Phenoxybenzamine.	Essential hypertension [BA00]	[13]
Nicardipine	DMCDYW7	Moderate	Increased risk of cardiac depression by the combination of Betaxolol and Nicardipine.	Essential hypertension [BA00]	[12]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of hyperglycemia by the combination of Betaxolol and Benzthiazide.	Essential hypertension [BA00]	[14]
Phenylephrine	DMZHUO5	Moderate	Additive hypertensive effects by the combination of Betaxolol and Phenylephrine.	Faecal incontinence [ME07]	[22]
Tolterodine	DMSHPW8	Moderate	Altered absorption of Betaxolol due to GI dynamics variation caused by Tolterodine.	Functional bladder disorder [GC50]	[16]
Propantheline	DM2EN6G	Moderate	Altered absorption of Betaxolol due to GI dynamics variation caused by Propantheline.	Gastric ulcer [DA60]	[16]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Betaxolol caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[23]
Spironolactone	DM2AQ5N	Moderate	Increased risk of hyperglycemia by the combination of Betaxolol and Spironolactone.	Heart failure [BD10-BD1Z]	[14]
Triamterene	DM2HU9I	Moderate	Increased risk of hyperglycemia by the combination of Betaxolol and Triamterene.	Heart failure [BD10-BD1Z]	[14]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Betaxolol and Prazosin.	Heart failure [BD10-BD1Z]	[13]
Chlorothiazide	DMLHESP	Moderate	Increased risk of hyperglycemia by the combination of Betaxolol and Chlorothiazide.	Heart failure [BD10-BD1Z]	[14]
Furosemide	DMMQ8ZG	Moderate	Increased risk of hyperglycemia by the combination of Betaxolol and Furosemide.	Heart failure [BD10-BD1Z]	[14]
Bumetanide	DMRV7H0	Moderate	Increased risk of hyperglycemia by the combination of Betaxolol and Bumetanide.	Heart failure [BD10-BD1Z]	[14]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of hyperglycemia by the combination of Betaxolol and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[14]
Torasemide	DMXKJ6C	Moderate	Increased risk of hyperglycemia by the combination of Betaxolol and Torasemide.	Heart failure [BD10-BD1Z]	[14]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Betaxolol caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[24]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Betaxolol when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[16]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Betaxolol and Propiomazine.	Insomnia [7A00-7A0Z]	[18]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Betaxolol and ITI-007.	Insomnia [7A00-7A0Z]	[18]
Clidinium	DMUMQZ0	Moderate	Additive CNS depression effects by the combination of Betaxolol and Clidinium.	Irritable bowel syndrome [DD91]	[16]
Dicyclomine	DMZSDGX	Moderate	Additive CNS depression effects by the combination of Betaxolol and Dicyclomine.	Irritable bowel syndrome [DD91]	[16]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Betaxolol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[16]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Betaxolol due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[21]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Betaxolol and Thalidomide.	Multiple myeloma [2A83]	[25]
Siponimod	DM2R86O	Major	Increased risk of bradycardia by the combination of Betaxolol and Siponimod.	Multiple sclerosis [8A40]	[25]
Fingolimod	DM5JVAN	Major	Increased risk of atrioventricular block by the combination of Betaxolol and Fingolimod.	Multiple sclerosis [8A40]	[26]
Ozanimod	DMT6AM2	Moderate	Increased risk of bradycardia by the combination of Betaxolol and Ozanimod.	Multiple sclerosis [8A40]	[27]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Betaxolol and Prochlorperazine.	Nausea/vomiting [MD90]	[18]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Betaxolol and Promethazine.	Nausea/vomiting [MD90]	[18]
Thiethylperazine	DMU3IET	Moderate	Additive hypotensive effects by the combination of Betaxolol and Thiethylperazine.	Nausea/vomiting [MD90]	[18]
Chlorthalidone	DM4DMBT	Moderate	Increased risk of ventricular arrhythmias by the combination of Betaxolol and Chlorthalidone.	Oedema [MG29]	[14]
Metolazone	DMB39LO	Moderate	Increased risk of ventricular arrhythmias by the combination of Betaxolol and Metolazone.	Oedema [MG29]	[14]
Polythiazide	DMCH80F	Moderate	Increased risk of hypertriglyceridemia by the combination of Betaxolol and Polythiazide.	Oedema [MG29]	[14]
Biperiden	DME78OA	Moderate	Antagonize the effect of Betaxolol when combined with Biperiden.	Parkinsonism [8A00]	[16]
Benztropine	DMGZOVN	Moderate	Antagonize the effect of Betaxolol when combined with Benztropine.	Parkinsonism [8A00]	[28]
Procyclidine	DMHFJDT	Moderate	Altered absorption of Betaxolol due to GI dynamics variation caused by Procyclidine.	Parkinsonism [8A00]	[16]
Methylscopolamine	DM5VWOB	Moderate	Altered absorption of Betaxolol due to GI dynamics variation caused by Methylscopolamine.	Peptic ulcer [DA61]	[16]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Betaxolol and Terazosin.	Prostate hyperplasia [GA90]	[13]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Betaxolol and Silodosin.	Prostate hyperplasia [GA90]	[13]
Alfuzosin	DMZVMKF	Moderate	Additive hypotensive effects by the combination of Betaxolol and Alfuzosin.	Prostate hyperplasia [GA90]	[13]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Betaxolol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[18]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Betaxolol and Fluphenazine.	Psychotic disorder [6A20-6A25]	[18]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Betaxolol and Triflupromazine.	Psychotic disorder [6A20-6A25]	[18]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Betaxolol caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[29]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Betaxolol and Quetiapine.	Schizophrenia [6A20]	[18]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Betaxolol and Mesoridazine.	Schizophrenia [6A20]	[18]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Betaxolol and Aripiprazole.	Schizophrenia [6A20]	[18]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Betaxolol and Iloperidone.	Schizophrenia [6A20]	[18]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Betaxolol and Paliperidone.	Schizophrenia [6A20]	[18]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Betaxolol and Loxapine.	Schizophrenia [6A20]	[18]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Betaxolol and Perphenazine.	Schizophrenia [6A20]	[18]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Betaxolol and Molindone.	Schizophrenia [6A20]	[18]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Betaxolol and Chlorpromazine.	Schizophrenia [6A20]	[18]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Betaxolol and Thiothixene.	Schizophrenia [6A20]	[18]
Clozapine	DMFC71L	Moderate	Additive hypotensive effects by the combination of Betaxolol and Clozapine.	Schizophrenia [6A20]	[18]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Betaxolol and Trifluoperazine.	Schizophrenia [6A20]	[18]
Ziprasidone	DMM58JY	Moderate	Additive hypotensive effects by the combination of Betaxolol and Ziprasidone.	Schizophrenia [6A20]	[18]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Betaxolol and Risperidone.	Schizophrenia [6A20]	[18]
Olanzapine	DMPFN6Y	Moderate	Additive hypotensive effects by the combination of Betaxolol and Olanzapine.	Schizophrenia [6A20]	[18]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Betaxolol and Amisulpride.	Schizophrenia [6A20]	[16]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Betaxolol and Asenapine.	Schizophrenia [6A20]	[18]
Succinylcholine	DM2ET1M	Moderate	Additive cardiorespiratory depression effects by the combination of Betaxolol and Succinylcholine.	Tonus and reflex abnormality [MB47]	[20]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Betaxolol and Pipecuronium.	Tonus and reflex abnormality [MB47]	[20]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Betaxolol and Doxacurium.	Tonus and reflex abnormality [MB47]	[20]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Betaxolol and Vecuronium.	Tonus and reflex abnormality [MB47]	[20]
Cisatracurium	DMUZPJ5	Moderate	Additive neuromuscular blocking effects by the combination of Betaxolol and Cisatracurium.	Tonus and reflex abnormality [MB47]	[20]
Trospium	DMX6RTG	Moderate	Antagonize the effect of Betaxolol when combined with Trospium.	Tonus and reflex abnormality [MB47]	[16]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Betaxolol and Rocuronium.	Tonus and reflex abnormality [MB47]	[20]
Atropine	DMEN6X7	Moderate	Antagonize the effect of Betaxolol when combined with Atropine.	Unspecific substance harmful effect [NE6Z]	[16]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Betaxolol and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[18]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Betaxolol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[30]
Disopyramide	DM5SYZP	Major	Increased risk of prolong QT interval by the combination of Betaxolol and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[31]
Amiodarone	DMUTEX3	Moderate	Increased risk of bradycardia by the combination of Betaxolol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[32]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acrylic acid	E00132	6581	Other agent
Hydrochloric acid	E00015	313	Acidulant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Benzalkonium chloride	E00536	21988052	Antimicrobial preservative; Penetration agent; Solubilizing agent; Surfactant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Edetate disodium	E00186	8759	Complexing agent
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Betaxolol 10 mg tablet	10 mg	Oral Tablet	Oral
Betaxolol 20 mg tablet	20 mg	Oral Tablet	Oral
Betaxolol Hydrochloride eq 0.25% base suspension	eq 0.25% base	Suspension	Ophthalmic
Betaxolol Hydrochloride 10mg tablet	10mg	Tablet	Oral
Betaxolol Hydrochloride eq 0.5% base solution	eq 0.5% base	Solution	Ophthalmic

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 549).
• [2] Betaxolol FDA Label
• [3] BDDCS applied to over 900 drugs
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [7] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [8] beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
• [9] Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol. 2007 Aug;21(4):437-43.
• [10] Drugs that may have potential CYP1A2 interactions.
• [11] Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
• [12] Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
• [13] Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
• [14] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
• [15] D'Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17. [PMID: 2886325]
• [16] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [17] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [18] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [19] Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
• [20] Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
• [21] Canadian Pharmacists Association.
• [22] Cass E, Kadar D, Stein HA "Hazards of phenylephrine topical medication in persons taking propranolol." Can Med Assoc J 120 (1979): 1261-2. [PMID: 221086]
• [23] Asgharnejad M, Powell R, Donn K, Danis M "The effect of cimetidine dose timing on oral propranolol kinetics in adults." Clin Pharmacol Ther 41 (1987): 203. [PMID: 3392231]
• [24] Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
• [25] Cerner Multum, Inc. "Australian Product Information.".
• [26] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [27] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [28] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
• [29] Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
• [30] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [31] Bonde J, Bodtker S, Angelo HR, Svedsen TL, Kampmann JP "Atenolol inhibits the elimination of disopyramide." Eur J Clin Pharmacol 28 (1985): 41-3. [PMID: 3987784]
• [32] Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]